In 2023, the European Association for the Study of the Liver (EASL) and the International Liver Cancer Association (ILCA) released the latest version of the "Clinical Practice Guidelines on the Management of Intrahepatic Cholangiocarcinoma" (referred to as "new version guidelines"). In comparison to the previous version of guidelines developed by EASL-ILCA in 2014 (referred to as "old version guidelines"), the new version guidelines adopt a new question-oriented article structure, accurately focusing on crucial clinical questions that urgently need to be answered in the field of intrahepatic cholangiocarcinoma (iCCA), especially those that are not covered by the old version guidelines or need to be updated based on recent scientific progress. In response to these questions, the new version guidelines proposed corresponding recommendations, providing substantial updates to clinical guidance for iCCA in respect of classification, risk factors, diagnosis, staging, and treatment. The purpose of this article is to provide a detailed interpretation of the key updates in the EASL-ILCA new version guidelines, and also to compare and discuss the relevant content of existing iCCA guidelines worldwide. Hopefully, it can continuously promote our in-depth understanding in the clinical practice of iCCA diagnosis and treatment.